The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience
Yıl: 2019 Cilt: 36 Sayı: 3 Sayfa Aralığı: 186 - 192 Metin Dili: İngilizce DOI: 10.4274/tjh.galenos.2019.2019.0090 İndeks Tarihi: 20-08-2020
The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience
Öz: Objective: Steroid-resistant acute graft-versus-host disease(srAGVHD) is the most important cause of morbidity and mortalityafter allogeneic stem cell transplantation. There are severaltreatment methods available, including mesenchymal stem cell (MSC)application. The aim of this study was to evaluate the results of MSCtherapy performed in children with srAGVHD.Materials and Methods: MSC therapy was used in our centerbetween November 2014 and December 2017 for 22 patients whodeveloped srAGVHD. The patients were retrospectively evaluated interms of treatment response and survival.Results: After application of MSCs, complete response was obtainedin 45.5% of the subjects, partial response was obtained in 13.6%,and no response was obtained in 40.9%. We found that 45.5% ofthe patients were alive and 54.5% had died and our treatment resultswere similar to those in the literature. Response to MSC treatment wasfound to be the only prognostic marker affecting mortality.Conclusion: MSC application is a treatment method that can beused safely together with other treatment methods in srAGVHD, acondition that has a high mortality rate. There are almost no acuteside effects. There are also no serious long-term side effects in theliterature. Prospective randomized studies are required to obtain highquality data.
Anahtar Kelime: Çocukluk Çağı Steroid Dirençli Akut Graft Versus-Host Hastalığında Allojenik Mezenkimal Kök Hücre Kullanımı: Retrospektif Bir Çalışma, Tek Merkez Deneyimi
Öz: Amaç: Steroid dirençli akut graft versus host hastalığı (sdAGVHH), allojenik kök hücre naklinden sonra en önemli morbidite ve mortalite nedenidir. Mezenkimal kök hücre (MKH) uygulaması da dahil olmak üzere çeşitli tedavi yöntemleri mevcuttur. Bu çalışmanın amacı, sdAGVHH’li çocuklarda yapılan MKH tedavisi sonuçlarını değerlendirmektir. Gereç ve Yöntemler: Merkezimizde sdAGVHH gelişen 22 hasta için Kasım 2014 - Aralık 2017 tarihleri arasında MKH tedavisi uygulandı. Hastalar tedaviye yanıt ve sağkalım yönünden retrospektif olarak değerlendirildi. Bulgular: MKH uygulanmasından sonra, deneklerin %45,5’inde tam cevap, %13,6’sında kısmi yanıt alınmıştır. Deneklerin %40,9’unda yanıt alınamamıştır. Hastaların %45,5’inin hayatta olduğunu ve %54,5’inin öldüğünü ve tedavi sonuçlarımızın literatürle benzer olduğunu bulduk. MKH tedavisine yanıt mortaliteyi etkileyen tek prognostik belirteç olarak bulundu. Sonuç: MKH uygulaması, mortalite oranı yüksek bir durum olan sdAGVHH’de diğer tedavi yöntemleriyle birlikte güvenle kullanılabilecek bir tedavi yöntemidir. Neredeyse hiçbir akut yan etkisi yoktur. Ayrıca literatürde uzun vadeli ciddi bir yan etkisi yoktur. Prospektif randomize çalışmalar, yüksek kaliteli veri elde etmek için gereklidir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Tekeli S, Naghavi EA, Gökçe B, Sır G, Yiğittürk G, Çavuşoğlu T, Uyanikgil Y. Kök hücreler; mezenkimal kök hücreler ve güncel klinik uygulamaları. FNG & Bilim Tıp Transplantasyon Dergisi 2016;1:72-83.
- 2. Dunavin N, Dias A, Li M, McGuirk J. Mesenchymal stromal cells: what is the mechanism in acute graft-versus-host disease? Biomedicines 2017:5.
- 3. Ma Y, Wang Z, Zhang A, Xu F, Zhao N, Xue J, Zhang H, Luan X. Human placenta-derived mesenchymal stem cells ameliorate GVHD by modulating Th17/Tr1 balance via expression of PD-L2. Life Sci 2018;214:98-105.
- 4. Fan X, Guo D, Cheung AMS, Poon ZY, Yap CS, Goh SE, Guo D, Li H, Bari S, Li S, Lim KH, Hwang WYK. Mesenchymal stromal cell (MSC)-derived combination of CXCL5 and anti-CCL24 is synergistic and superior to MSC and cyclosporine for the treatment of graft-versus-host disease. Biol Blood Marrow Transplant 2018;24:1971-1980.
- 5. Su J, Chen X, Huang Y, Li W, Li J, Cao K, Cao G, Zhang L, Li F, Roberts AI, Kang H, Yu P, Ren G, Ji W, Wang Y, Shi Y. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differen 2014;21:388-396.
- 6. Rowlings PA, Przepiorka D, Kleinetal JP, Gale RP, Passweg JR, HensleeDowney PJ, Cahn JY, Calderwood S, Gratwohl A, Socié G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;4:855-864.
- 7. Kabataş S, Civelek E, İnci Ç, Yalçınkaya EY, Günel G, Kır G, Albayrak E, Öztürk E, Adaş G, Karaöz E. Wharton’s jelly-derived mesenchymal stem cell transplantation in a patient with hypoxic-ischemic encephalopathy: a pilot study. Cell Transplant 2018;27:1425-1433.
- 8. Dai A, Baspinar O, Yeşilyurt A, Sun E, Aydemir Çİ, Öztel ON, Capkan DU, Pinarli F, Agar A, Karaöz E. Efficacy of stem cell therapy in ambulatory and nonambulatory children with Duchenne muscular dystrophy - Phase I-II. Degener Neurol Neuromuscul Dis 2018;8:63-77.
- 9. Okur SÇ, Erdoğan S, Demir CS, Günel G, Karaöz E. The effect of umbilical cord-derived mesenchymal stem cell transplantation in a patient with cerebral palsy: a case report. Int J Stem Cells 2018;11:141-147.
- 10. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010;16:838-847.
- 11. Gao L, Zhang Y, Hu B, Liu J, Kong P, Lou S, Su Y, Yang T, Li H, Liu Y, Zhang C, Gao L, Zhu L, Wen Q, Wang P, Chen X, Zhong J, Zhang X. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J Clin Oncol 2016;34:2843-2850.
- 12. Wang L, Zhu CY, Ma DX, Gu ZY, Xu CC, Wang FY, Chen JG, Liu CJ, Guan LX, Gao R, Gao Z, Fang S, Zhuo DJ, Liu SF, Gao CJ. Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a metaanalysis of randomized controlled trials. Ann Hematol 2018;97:1941- 1950.
- 13. Dotoli GM, De Santis GC, Orellana MD, de Lima Prata K, Caruso SR, Fernandes TR, Rensi Colturato VA, Kondo AT, Hamerschlak N, Simões BP, Covas DT. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant 2017;52:859-862.
- 14. Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, Horn B, Yu L, Talano JA, Nemecek E, Mills CR, Chaudhury S. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant 2014;20:229-235.
- 15. Thielen FW, Blommestein HM, Oosten LEM, Calkoen FG, Lankester AC, Zwaginga JJ, Le Blanc K, Redondo A, Sánchez-Guijo F, Algeri M, Locatelli F, Fibbe WE, Uyl-de Groot CA. Second-line treatment for acute graftversus-host disease with mesenchymal stromal cells: a decision model. Eur J Haematol 2018.
- 16. Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, Longoni D, Pavan F, Masciocchi F, Algarotti A, Micò C, Grassi A, Deola S, Cavattoni I, Gaipa G, Belotti D, Perseghin P, Parma M, Pogliani E, Golay J, Pedrini O, Capelli C, Cortelazzo S, D’Amico G, Biondi A, Rambaldi A, Biagi E. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 2014;20:375-381.
- 17. Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, PérezSimon JA. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2014;20:1580-1585.
- 18. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, Mankuta D, Bloom NV, Rheingold L, Yeshurun M, Bielorai B, Toren A, Zuckerman T, Nagler A, Or R. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res 2013;3:225- 238.
- 19. Rizk M, Monaghan M, Shorr R, Kekre N, Bredeson CN, Allan DS. Heterogeneity in studies of mesenchymal stromal cells to treat or prevent graft-versus-host disease: a scoping review of the evidence. Biol Blood Marrow Transplant 2016;22:1416-1423.
- 20. Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F. Manufacturing mesenchymal stromal cells for the treatment of graft-versus-host disease: a survey among centers affiliated with the european society for blood and marrow transplantation. Biol Blood Marrow Transplant 2018;24:2365-2370.
- 21. Kuçi Z, Bönig H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, Škifić M, Michel K, Eising B, Lucchini G, Bakhtiar S, Greil J, Lang P, Basu O, von Luettichau I, Schulz A, Sykora KW, Jarisch A, Soerensen J, SalzmannManrique E, Seifried E, Klingebiel T, Bader P, Kuçi S. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica 2016;101:985-994.
- 22. Erbey F, Atay D, Akcay A, Ovali E, Ozturk G. Mesenchymal stem cell treatment for steroid refractory graft-versus-host disease in children: a pilot and first study from Turkey. Stem Cells Int 2016;2016:1641402.
- 23. Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, Avanzini MA, Conforti A, Bertaina A, Giorgiani G, Jol-van der Zijde CM, Zecca M, Le Blanc K, Frassoni F, Egeler RM, Fibbe WE, Lankester AC, Locatelli F. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graftversus-host disease. Br J Haematol 2013;163:501-509.
- 24. Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, Itoh J, Umezawa A, Kijima H, Fukuda S, Saijo Y. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med 2011;17:579-587.
- 25. Brennen WN, Chen S, Denmeade S, Isaacs JT. Quantification of mesenchymal stem cells (MSCs) at sites of human prostate cancer. Oncotarget 2013;4:106- 117.
- 26. Stoma I, Karpov I, Krivenko S, Iskrov I, Milanovich N, Koritko A, Uss A. Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. Ann Hematol 2018;97:885-891.
- 27. Schmidt S, Tramsen L, Schneider A, Schubert R, Balan A, Degistirici Ö, Meisel R, Lehrnbecher T. Impact of human mesenchymal stromal cells on antifungal host response against Aspergillus fumigatus. Oncotarget 2017;8:95495- 95503.
| APA | Bozkurt C, Karaoz E, Adaklı Aksoy B, Aydogdu S, FISGIN T (2019). The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. , 186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| Chicago | Bozkurt Ceyhun,Karaoz Erdal,Adaklı Aksoy Başak,Aydogdu Selime,FISGIN TUNC The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. (2019): 186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| MLA | Bozkurt Ceyhun,Karaoz Erdal,Adaklı Aksoy Başak,Aydogdu Selime,FISGIN TUNC The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. , 2019, ss.186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| AMA | Bozkurt C,Karaoz E,Adaklı Aksoy B,Aydogdu S,FISGIN T The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. . 2019; 186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| Vancouver | Bozkurt C,Karaoz E,Adaklı Aksoy B,Aydogdu S,FISGIN T The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. . 2019; 186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| IEEE | Bozkurt C,Karaoz E,Adaklı Aksoy B,Aydogdu S,FISGIN T "The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience." , ss.186 - 192, 2019. 10.4274/tjh.galenos.2019.2019.0090 |
| ISNAD | Bozkurt, Ceyhun vd. "The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience". (2019), 186-192. https://doi.org/10.4274/tjh.galenos.2019.2019.0090 |
| APA | Bozkurt C, Karaoz E, Adaklı Aksoy B, Aydogdu S, FISGIN T (2019). The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. Turkish Journal of Hematology, 36(3), 186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| Chicago | Bozkurt Ceyhun,Karaoz Erdal,Adaklı Aksoy Başak,Aydogdu Selime,FISGIN TUNC The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. Turkish Journal of Hematology 36, no.3 (2019): 186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| MLA | Bozkurt Ceyhun,Karaoz Erdal,Adaklı Aksoy Başak,Aydogdu Selime,FISGIN TUNC The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. Turkish Journal of Hematology, vol.36, no.3, 2019, ss.186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| AMA | Bozkurt C,Karaoz E,Adaklı Aksoy B,Aydogdu S,FISGIN T The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. Turkish Journal of Hematology. 2019; 36(3): 186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| Vancouver | Bozkurt C,Karaoz E,Adaklı Aksoy B,Aydogdu S,FISGIN T The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience. Turkish Journal of Hematology. 2019; 36(3): 186 - 192. 10.4274/tjh.galenos.2019.2019.0090 |
| IEEE | Bozkurt C,Karaoz E,Adaklı Aksoy B,Aydogdu S,FISGIN T "The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience." Turkish Journal of Hematology, 36, ss.186 - 192, 2019. 10.4274/tjh.galenos.2019.2019.0090 |
| ISNAD | Bozkurt, Ceyhun vd. "The Use of Allogeneic Mesenchymal Stem Cells in Childhood Steroid-Resistant Acute Graft-Versus-Host Disease: A Retrospective Study of a Single-Center Experience". Turkish Journal of Hematology 36/3 (2019), 186-192. https://doi.org/10.4274/tjh.galenos.2019.2019.0090 |
